Estrogen receptors (α and β) and 17β-hydroxysteroid dehydrogenase Type 1 and 2 in thyroid disorders

Possible in situ estrogen synthesis and actions

Wakako Kawabata, Takashi Suzuki, Takuya Moriya, Keisei Fujimori, Hiroshi Naganuma, Satoshi Inoue, Yositaka Kinouchi, Kaori Kameyama, Hiroshi Takami, Tooru Shimosegawa, Hironobu Sasano

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Both epidemiological and experimental findings suggest the possible roles of sex steroids in the pathogenesis and/or development of various human thyroid disorders. In this study, we evaluated the expression of estrogen receptors (ER) α and β in normal thyroid glands (N = 25; female: n = 13, male: n = 10, unknown: n = 2) ranging in age from fetus to adult. Furthermore, using immunohistochemistry, we investigated the expression of ERα and β in 206 cases of thyroid disorders, including 24 adenomatous goiters, 23 follicular adenomas, and 159 thyroid carcinomas. In addition, we also studied the mRNA expression of ERα and β and 17β-hydroxysteroid dehydrogenase Type 1 and 2, enzymes involved in the interconversion between estrone and estradiol, using reverse transcription polymerase chain reaction (RT-PCR), in 48 of these 206 cases (10 adenomatous goiters, 10 follicular adenomas, and 28 papillary thyroid carcinomas) in which fresh frozen tissues were available for examination to further elucidate the possible involvement of intracrine estrogen metabolism and/or actions in thyroid disorders. ERα labeling index, or percentage of cells immunopositive for ERα, was significantly higher in adenomatous goiter (14.2 ± 6.4), follicular adenoma (13.4 ± 5.1), and thyroid carcinoma (16.4 ± 2.1) than in normal thyroid gland (0; P < .05). Few follicular cells were positive for ERα in normal thyroid glands. In papillary carcinoma, ERα labeling index was significantly higher in premenopausal women (28.1 ± 4.5) than in postmenopausal women (14.2 ± 2.9) and in men of various ages (7.6 ± 2.7; P < .05). In other histological types of thyroid carcinoma, no significant correlations were detected. ERβ immunoreactivity was detected in both follicular and C-cells of normal thyroid glands, including those in developing fetal thyroid glands. In addition, ERβ immunoreactivity was detected in the nuclei of various thyroid lesions. But no significant correlations were detected between ERβ labeling index and clinicopathological findings including age, menopausal status, gender, and/or histological type of thyroid lesions. 17β-hydroxysteroid dehydrogenase Type 1 expression was detected in 31/48 (64.0%) of the cases examined, whereas Type 2 was detected only in 3/46 (6.3%) of all the cases examined. These results demonstrated that estrogens may influence the development, physiology, and pathology of human thyroid glands, and these effects, especially through ERα, may become more pronounced in neoplasms, particularly in papillary carcinoma arising in premenopausal women.

Original languageEnglish
Pages (from-to)437-444
Number of pages8
JournalModern Pathology
Volume16
Issue number5
DOIs
Publication statusPublished - 2003 May 1

Fingerprint

Estrogen Receptors
Thyroid Gland
Estrogens
Goiter
Thyroid Neoplasms
Adenoma
Papillary Carcinoma
3(17)-hydroxysteroid dehydrogenase
Estrone
Human Development
Reverse Transcription
Estradiol
Fetus
Immunohistochemistry
Steroids
Pathology
Polymerase Chain Reaction
Messenger RNA
Enzymes

Keywords

  • 17β-hydroxysteroid dehydrogenase
  • Estrogen receptors
  • Human thyroid lesions
  • Immunohistochemistry
  • Labeling index
  • Reverse transcription polymerase chain reaction

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Estrogen receptors (α and β) and 17β-hydroxysteroid dehydrogenase Type 1 and 2 in thyroid disorders : Possible in situ estrogen synthesis and actions. / Kawabata, Wakako; Suzuki, Takashi; Moriya, Takuya; Fujimori, Keisei; Naganuma, Hiroshi; Inoue, Satoshi; Kinouchi, Yositaka; Kameyama, Kaori; Takami, Hiroshi; Shimosegawa, Tooru; Sasano, Hironobu.

In: Modern Pathology, Vol. 16, No. 5, 01.05.2003, p. 437-444.

Research output: Contribution to journalArticle

Kawabata, W, Suzuki, T, Moriya, T, Fujimori, K, Naganuma, H, Inoue, S, Kinouchi, Y, Kameyama, K, Takami, H, Shimosegawa, T & Sasano, H 2003, 'Estrogen receptors (α and β) and 17β-hydroxysteroid dehydrogenase Type 1 and 2 in thyroid disorders: Possible in situ estrogen synthesis and actions', Modern Pathology, vol. 16, no. 5, pp. 437-444. https://doi.org/10.1097/01.MP.0000066800.44492.1B
Kawabata, Wakako ; Suzuki, Takashi ; Moriya, Takuya ; Fujimori, Keisei ; Naganuma, Hiroshi ; Inoue, Satoshi ; Kinouchi, Yositaka ; Kameyama, Kaori ; Takami, Hiroshi ; Shimosegawa, Tooru ; Sasano, Hironobu. / Estrogen receptors (α and β) and 17β-hydroxysteroid dehydrogenase Type 1 and 2 in thyroid disorders : Possible in situ estrogen synthesis and actions. In: Modern Pathology. 2003 ; Vol. 16, No. 5. pp. 437-444.
@article{4d7d3280b1af45bcbc4a12de545729f0,
title = "Estrogen receptors (α and β) and 17β-hydroxysteroid dehydrogenase Type 1 and 2 in thyroid disorders: Possible in situ estrogen synthesis and actions",
abstract = "Both epidemiological and experimental findings suggest the possible roles of sex steroids in the pathogenesis and/or development of various human thyroid disorders. In this study, we evaluated the expression of estrogen receptors (ER) α and β in normal thyroid glands (N = 25; female: n = 13, male: n = 10, unknown: n = 2) ranging in age from fetus to adult. Furthermore, using immunohistochemistry, we investigated the expression of ERα and β in 206 cases of thyroid disorders, including 24 adenomatous goiters, 23 follicular adenomas, and 159 thyroid carcinomas. In addition, we also studied the mRNA expression of ERα and β and 17β-hydroxysteroid dehydrogenase Type 1 and 2, enzymes involved in the interconversion between estrone and estradiol, using reverse transcription polymerase chain reaction (RT-PCR), in 48 of these 206 cases (10 adenomatous goiters, 10 follicular adenomas, and 28 papillary thyroid carcinomas) in which fresh frozen tissues were available for examination to further elucidate the possible involvement of intracrine estrogen metabolism and/or actions in thyroid disorders. ERα labeling index, or percentage of cells immunopositive for ERα, was significantly higher in adenomatous goiter (14.2 ± 6.4), follicular adenoma (13.4 ± 5.1), and thyroid carcinoma (16.4 ± 2.1) than in normal thyroid gland (0; P < .05). Few follicular cells were positive for ERα in normal thyroid glands. In papillary carcinoma, ERα labeling index was significantly higher in premenopausal women (28.1 ± 4.5) than in postmenopausal women (14.2 ± 2.9) and in men of various ages (7.6 ± 2.7; P < .05). In other histological types of thyroid carcinoma, no significant correlations were detected. ERβ immunoreactivity was detected in both follicular and C-cells of normal thyroid glands, including those in developing fetal thyroid glands. In addition, ERβ immunoreactivity was detected in the nuclei of various thyroid lesions. But no significant correlations were detected between ERβ labeling index and clinicopathological findings including age, menopausal status, gender, and/or histological type of thyroid lesions. 17β-hydroxysteroid dehydrogenase Type 1 expression was detected in 31/48 (64.0{\%}) of the cases examined, whereas Type 2 was detected only in 3/46 (6.3{\%}) of all the cases examined. These results demonstrated that estrogens may influence the development, physiology, and pathology of human thyroid glands, and these effects, especially through ERα, may become more pronounced in neoplasms, particularly in papillary carcinoma arising in premenopausal women.",
keywords = "17β-hydroxysteroid dehydrogenase, Estrogen receptors, Human thyroid lesions, Immunohistochemistry, Labeling index, Reverse transcription polymerase chain reaction",
author = "Wakako Kawabata and Takashi Suzuki and Takuya Moriya and Keisei Fujimori and Hiroshi Naganuma and Satoshi Inoue and Yositaka Kinouchi and Kaori Kameyama and Hiroshi Takami and Tooru Shimosegawa and Hironobu Sasano",
year = "2003",
month = "5",
day = "1",
doi = "10.1097/01.MP.0000066800.44492.1B",
language = "English",
volume = "16",
pages = "437--444",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Estrogen receptors (α and β) and 17β-hydroxysteroid dehydrogenase Type 1 and 2 in thyroid disorders

T2 - Possible in situ estrogen synthesis and actions

AU - Kawabata, Wakako

AU - Suzuki, Takashi

AU - Moriya, Takuya

AU - Fujimori, Keisei

AU - Naganuma, Hiroshi

AU - Inoue, Satoshi

AU - Kinouchi, Yositaka

AU - Kameyama, Kaori

AU - Takami, Hiroshi

AU - Shimosegawa, Tooru

AU - Sasano, Hironobu

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Both epidemiological and experimental findings suggest the possible roles of sex steroids in the pathogenesis and/or development of various human thyroid disorders. In this study, we evaluated the expression of estrogen receptors (ER) α and β in normal thyroid glands (N = 25; female: n = 13, male: n = 10, unknown: n = 2) ranging in age from fetus to adult. Furthermore, using immunohistochemistry, we investigated the expression of ERα and β in 206 cases of thyroid disorders, including 24 adenomatous goiters, 23 follicular adenomas, and 159 thyroid carcinomas. In addition, we also studied the mRNA expression of ERα and β and 17β-hydroxysteroid dehydrogenase Type 1 and 2, enzymes involved in the interconversion between estrone and estradiol, using reverse transcription polymerase chain reaction (RT-PCR), in 48 of these 206 cases (10 adenomatous goiters, 10 follicular adenomas, and 28 papillary thyroid carcinomas) in which fresh frozen tissues were available for examination to further elucidate the possible involvement of intracrine estrogen metabolism and/or actions in thyroid disorders. ERα labeling index, or percentage of cells immunopositive for ERα, was significantly higher in adenomatous goiter (14.2 ± 6.4), follicular adenoma (13.4 ± 5.1), and thyroid carcinoma (16.4 ± 2.1) than in normal thyroid gland (0; P < .05). Few follicular cells were positive for ERα in normal thyroid glands. In papillary carcinoma, ERα labeling index was significantly higher in premenopausal women (28.1 ± 4.5) than in postmenopausal women (14.2 ± 2.9) and in men of various ages (7.6 ± 2.7; P < .05). In other histological types of thyroid carcinoma, no significant correlations were detected. ERβ immunoreactivity was detected in both follicular and C-cells of normal thyroid glands, including those in developing fetal thyroid glands. In addition, ERβ immunoreactivity was detected in the nuclei of various thyroid lesions. But no significant correlations were detected between ERβ labeling index and clinicopathological findings including age, menopausal status, gender, and/or histological type of thyroid lesions. 17β-hydroxysteroid dehydrogenase Type 1 expression was detected in 31/48 (64.0%) of the cases examined, whereas Type 2 was detected only in 3/46 (6.3%) of all the cases examined. These results demonstrated that estrogens may influence the development, physiology, and pathology of human thyroid glands, and these effects, especially through ERα, may become more pronounced in neoplasms, particularly in papillary carcinoma arising in premenopausal women.

AB - Both epidemiological and experimental findings suggest the possible roles of sex steroids in the pathogenesis and/or development of various human thyroid disorders. In this study, we evaluated the expression of estrogen receptors (ER) α and β in normal thyroid glands (N = 25; female: n = 13, male: n = 10, unknown: n = 2) ranging in age from fetus to adult. Furthermore, using immunohistochemistry, we investigated the expression of ERα and β in 206 cases of thyroid disorders, including 24 adenomatous goiters, 23 follicular adenomas, and 159 thyroid carcinomas. In addition, we also studied the mRNA expression of ERα and β and 17β-hydroxysteroid dehydrogenase Type 1 and 2, enzymes involved in the interconversion between estrone and estradiol, using reverse transcription polymerase chain reaction (RT-PCR), in 48 of these 206 cases (10 adenomatous goiters, 10 follicular adenomas, and 28 papillary thyroid carcinomas) in which fresh frozen tissues were available for examination to further elucidate the possible involvement of intracrine estrogen metabolism and/or actions in thyroid disorders. ERα labeling index, or percentage of cells immunopositive for ERα, was significantly higher in adenomatous goiter (14.2 ± 6.4), follicular adenoma (13.4 ± 5.1), and thyroid carcinoma (16.4 ± 2.1) than in normal thyroid gland (0; P < .05). Few follicular cells were positive for ERα in normal thyroid glands. In papillary carcinoma, ERα labeling index was significantly higher in premenopausal women (28.1 ± 4.5) than in postmenopausal women (14.2 ± 2.9) and in men of various ages (7.6 ± 2.7; P < .05). In other histological types of thyroid carcinoma, no significant correlations were detected. ERβ immunoreactivity was detected in both follicular and C-cells of normal thyroid glands, including those in developing fetal thyroid glands. In addition, ERβ immunoreactivity was detected in the nuclei of various thyroid lesions. But no significant correlations were detected between ERβ labeling index and clinicopathological findings including age, menopausal status, gender, and/or histological type of thyroid lesions. 17β-hydroxysteroid dehydrogenase Type 1 expression was detected in 31/48 (64.0%) of the cases examined, whereas Type 2 was detected only in 3/46 (6.3%) of all the cases examined. These results demonstrated that estrogens may influence the development, physiology, and pathology of human thyroid glands, and these effects, especially through ERα, may become more pronounced in neoplasms, particularly in papillary carcinoma arising in premenopausal women.

KW - 17β-hydroxysteroid dehydrogenase

KW - Estrogen receptors

KW - Human thyroid lesions

KW - Immunohistochemistry

KW - Labeling index

KW - Reverse transcription polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=0038823620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038823620&partnerID=8YFLogxK

U2 - 10.1097/01.MP.0000066800.44492.1B

DO - 10.1097/01.MP.0000066800.44492.1B

M3 - Article

VL - 16

SP - 437

EP - 444

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 5

ER -